Clinical Trials Logo
  1. Home
  2. Hepatitis C
  3. NCT03444272
  4. Details
NCT03444272 Clinical Trial

Effect of Direct-acting Antiviral Drugs on Erectile Function

Hepatitis C Clinical Trial

Official title:
Effect of Direct-acting Antiviral Drugs on Erectile Function Among Hepatitis c Patients

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03444272
Other study ID # HCV TREATMENT
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date January 1, 2018
Est. completion date December 2022

Study information
Verified date October 2020
Source Tanta University
Contact Sherief Abd-Elsalam, MD
Phone 00201095159522
Email sheriefabdelsalam@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Effect of direct-acting antiviral drugs on erectile function

Description:

Effect of direct-acting antiviral drugs on erectile function in HCV patients

Recruitment information / eligibility
Status Recruiting
Enrollment 105
Est. completion date December 2022
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - HCV infected patients - Male Exclusion Criteria: - HCC - Age below 18 years

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Sofosbuvir and Daklatasuvir
HCV Treatment (Sofosbuvir and Daklatasuvir)

Locations
Country Name City State
Egypt Sherief Abd-Elsalam Tanta

Sponsors (2)
Lead Sponsor Collaborator
Sherief Abd-Elsalam Benha University

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary Number of patients with improved erectile functions Number of patients with improved erectile functions 6 months
See also
  Status Clinical Trial Phase
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Recruiting NCT04510246 - Link Hepatitis C Notifications to Treatment in Tasmania N/A
Completed NCT03413696 - Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
Completed NCT03118674 - Harvoni Treatment Porphyria Cutanea Tarda Phase 2
Completed NCT03109457 - Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
Completed NCT01458054 - Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults Phase 1
Completed NCT03740230 - An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
Completed NCT03426787 - Helping Empower Liver and Kidney Patients N/A
Completed NCT03627299 - Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors Phase 4
Completed NCT00006301 - Immune Response to Hepatitis C Virus
Active, not recruiting NCT03949764 - The Kentucky Viral Hepatitis Treatment Study Phase 4
Completed NCT03365635 - Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C Phase 4
Recruiting NCT04405024 - Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients N/A
Completed NCT04525690 - Improving Inpatient Screening for Hepatitis C N/A
Completed NCT04033887 - Evaluation Study of RDTs Detecting Antibodies Against HCV
Withdrawn NCT04546802 - HepATocellular Cancer Hcv Therapy Study Phase 3
Active, not recruiting NCT02961426 - Strategic Transformation of the Market of HCV Treatments Phase 2/Phase 3
Completed NCT03186313 - A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection Phase 3
Completed NCT02705534 - Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 Phase 3
Completed NCT02992184 - PoC-HCV Genedrive Viral Detection Assay Validation Study N/A